Temozolomide hexadecyl ester targeted plga nanoparticles for drug-resistant glioblastoma therapy via intranasal administration
Introduction: Temozolomide (TMZ) is the first-line drug for glioblastoma (GBM), but it is limited in clinical use due to the drug resistance, poor brain targeting, and side effects. Temozolomide hexadecyl ester (TMZ16e), a TMZ derivative with high lipophilicity, membrane permeability, and high anti-...
Saved in:
Main Authors: | Siqi Wang (Author), Yawen Yu (Author), Aiping Wang (Author), Xinliu Duan (Author), Yuchen Sun (Author), Liangxiao Wang (Author), Liuxiang Chu (Author), Yanan Lv (Author), Nan Cui (Author), Xuesong Fan (Author), Chunjie Sha (Author), Lixiao Xu (Author), Kaoxiang Sun (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Nose-to-brain delivery of temozolomide-loaded PLGA nanoparticles functionalized with anti-EPHA3 for glioblastoma targeting
by: Liuxiang Chu, et al.
Published: (2018) -
Brain-targeted intranasal delivery of dopamine with borneol and lactoferrin co-modified nanoparticles for treating Parkinson's disease
by: Shengnan Tang, et al.
Published: (2019) -
Factorial Design as a Tool for the Optimization of PLGA Nanoparticles for the Co-Delivery of Temozolomide and O6-Benzylguanine
by: Maria João Ramalho, et al.
Published: (2019) -
Advances in the management of glioblastoma: the role of temozolomide and MGMT testing
by: Thomas RP, et al.
Published: (2012) -
Aberrant Expression of ADARB1 Facilitates Temozolomide Chemoresistance and Immune Infiltration in Glioblastoma
by: Can Lu, et al.
Published: (2022)